Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
FDA establishment 3008808745, Ho Chi Minh, Vietnam. Part of Rohto-Mentholatum (Vietnam)'s FDA records. Every inspection FDA has posted for the site, with its outcome and cited regulations and its recalls since 2016.
Inspections: 5
Official action indicated: 2
Last inspection ended: Apr 14, 2026
Warning letters: 1
Recalls since 2016: 1
Inspections by Fiscal Year
FY2018 to FY2027 to date; 1 classified OAI
How to read this
A hatched bar is a year that is not over, so its count covers only part of the year.
21 CFR 211.42(c)(10)(iv). Environmental Monitoring System Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
21 CFR 211.42(c)(10)(v). Cleaning System Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the equipment to produce aseptic conditions.
21 CFR 211.100(a). Absence of Written Procedures Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.
21 CFR 211.194(a). Complete test data included in records Laboratory records do not include complete data derived from all tests, examinations and assay necessary to assure compliance with established specifications and standards.
21 CFR 211.113(b). Procedures for sterile drug products Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not followed.
21 CFR 211.113(b). Validation lacking for sterile drug products Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic process.
21 CFR 211.192. Investigations of discrepancies, failures There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.
21 CFR 211.42(c)(10)(i). Floors, walls, ceiling surfaces Aseptic processing areas are deficient in that ceilings are not smooth and/or hard surfaces that are easily cleanable.
Official Action Indicated (OAI)
Nov 1, 2019
Drugs · Drug Quality Assurance
None posted
Voluntary Action Indicated (VAI)
Mar 16, 2018
Drugs · Drug Quality Assurance
None posted
Voluntary Action Indicated (VAI)
Apr 14, 2015
Drugs · Drug Quality Assurance
None posted
Voluntary Action Indicated (VAI)
May 15, 2012
Drugs · Drug Quality Assurance
13 cited references
21 CFR 211.194(a)(2). Suitability of testing methods verified The suitability of all testing methods is not verified under actual conditions of use.
21 CFR 211.150. Written distribution procedure Written distribution procedures are not established.
21 CFR 211.137(b). Storage conditions Drug product expiration dates are not related to the storage conditions stated on the labeling, as determined by stability studies.
21 CFR 211.42(c)(10). Aseptic Processing Area Separate or defined areas to prevent contamination or mix-ups are deficient regarding operations related to aseptic processing of drug products.
21 CFR 211.160(b). Scientifically sound laboratory controls Laboratory controls do not include the establishment of scientifically sound and appropriate test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity.
21 CFR 211.192. Investigations of discrepancies, failures There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
21 CFR 211.84(c)(4). Top/Middle/Bottom container sampling Sampling procedures are deficient regarding sampling components from the top, middle, and bottom of container.
21 CFR 211.160(a). Following/documenting laboratory controls Established laboratory control mechanisms are not documented at the time of performance.
21 CFR 211.80(a). Written Procedures Not Followed Written procedures are not followed for the receipt, identification, storage, handling, and sampling of components, drug product containers, and closures.
21 CFR 211.160(b)(2). In-process sample representation/identification In-process samples are not representative.
21 CFR 211.186(b)(7). Theoretical yield statement including percentages Master production and control records lack a statement of theoretical yield including the maximum and minimum percentages of theoretical yield beyond which investigation is required.
21 CFR 211.194(a)(4). Data secured in course of each test Laboratory records do not include a complete record of all data secured in the course of each test, including all graphs, charts, and spectra from laboratory instrumentation, properly identified to show the specific component, in-process material, lot tested, and drug product tested.
21 CFR 211.194(a)(7). Signatures and dates--person who performs test Laboratory records do not include the initials or signature of the person who performs each test.
Official Action Indicated (OAI)
Warning Letters
Letters naming this establishment; each opens the letter
An FEI (FDA Establishment Identifier) names one physical site. Inspections, outcomes and citations come from FDA's Data Dashboard; FDA posts citations only for some inspections. Recalls come from FDA's enforcement reports (iRES), one row per recall even when it covers many lots. A contract site can make products for many companies, so the company shown is the one FDA lists as the site's firm.FDA Data Dashboard, warning letters and enforcement reports